billHR5269•Event Wednesday, September 10, 2025Analyzed

RESULTS Act

Neutral

Impact4/10

$LH $DGX $QGEN Thermo Fisher Scientific ($TMO)Healthcare

Summary

The RESULTS Act (HR5269) aims to stabilize Medicare reimbursement rates for clinical diagnostic laboratory tests, preventing future payment reductions. This bill is in the early stages of the legislative process, having been introduced and referred to two House committees. Its current impact on market prices for diagnostic testing companies is not yet significant due to its early legislative stage.

Key Takeaways

1.The RESULTS Act (HR5269) aims to stabilize Medicare reimbursement for clinical diagnostic laboratory tests, benefiting diagnostic testing companies.
2.The bill is in the early stages of the legislative process, having been referred to two House committees, and has a companion bill (S2761) in the Senate.
3.No direct funding is authorized or appropriated by this bill; its impact is through regulatory changes to payment methodologies.
4.Companies like Labcorp Holdings Inc. ($LH), Quest Diagnostics Incorporated ($DGX), Qiagen N.V. ($QGEN), and Thermo Fisher Scientific Inc. ($TMO) are structural beneficiaries if the bill passes.

Market Implications

The RESULTS Act, if enacted, would provide long-term stability for Medicare reimbursement rates for clinical diagnostic laboratory tests. This regulatory certainty would be structurally beneficial for companies heavily reliant on Medicare payments for these services. Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX) are primary examples, as more predictable reimbursement rates could improve their revenue visibility and financial planning. While the bill is still in its early legislative stages, its progression could eventually reduce a key source of financial uncertainty for the diagnostic testing sector. Currently, the market data for $LH, $DGX, $QGEN, and $TMO shows varied short-term performance, with 7-day changes ranging from +0.91% to +4.12% and 30-day changes ranging from -12.19% to -0.53%. These movements are not directly attributable to the RESULTS Act at this time, as the bill's impact is prospective and contingent on its passage. The presence of a companion bill in the Senate (S2761) suggests a coordinated effort to address this issue, which could increase the long-term probability of some form of legislation being enacted.

Full Analysis

The RESULTS Act (HR5269), introduced on September 10, 2025, seeks to amend the Social Security Act to provide long-term stability for Medicare beneficiary access to clinical diagnostic laboratory tests. The bill's primary mechanism is to improve the accuracy and feasibility of data collection for private payor-based fee schedule payment rates applied under Medicare for such tests. It has been referred to the House Committees on Energy and Commerce and Ways and Means. A companion bill, S2761, has been introduced in the Senate and referred to the Committee on Finance, indicating bipartisan and bicameral interest in the issue. This bill does not authorize or appropriate a specific funding amount. Instead, it focuses on regulatory changes to the payment methodology for clinical diagnostic laboratory tests under Medicare. The intent is to stabilize reimbursement rates, which would provide a more predictable revenue stream for companies operating in this sector. The mechanism involves modifying how data is acquired for widely available non-advanced diagnostic laboratory tests, specifically from a qualifying comprehensive claims database of an independent national nonprofit entity. Structural beneficiaries of this legislation, should it pass, would be companies involved in clinical diagnostic laboratory testing. These include Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX), which are major providers of such services. Companies that supply diagnostic equipment and reagents, such as Qiagen N.V. ($QGEN) and Thermo Fisher Scientific Inc. ($TMO), could also see indirect benefits from a more stable and predictable reimbursement environment for their customers. The bill's aim to prevent future payment reductions would reduce financial uncertainty for these businesses. Based on recent market data, Labcorp Holdings Inc. ($LH) is currently trading at $274.46, showing a 7-day change of +4.12% and a 30-day change of -0.53%. Quest Diagnostics Incorporated ($DGX) is at $198.96, with a 7-day change of +0.91% and a 30-day change of -2.46%. Qiagen N.V. ($QGEN) is at $40.78, with a 7-day change of +3.71% and a 30-day change of -12.19%. Thermo Fisher Scientific Inc. ($TMO) is at $488.19, with a 7-day change of +1.7% and a 30-day change of -5.91%. These recent price movements do not directly reflect the RESULTS Act, given its early legislative stage. The bill's early status means it has a long path through committees, potential floor votes, and reconciliation with its Senate companion, S2761, before it could become law. Key legislative steps remaining include committee hearings, markups, potential amendments, and votes in both the House and Senate. Given the bill was introduced in September 2025, it is still in the initial phase of a multi-year legislative process. The presence of 69 cosponsors, including members from both parties, suggests a degree of bipartisan support, which could aid its progression.